Rare mutations in the TP73 gene, which is involved in the regulation of a cell’s life cycle, may put a person at greater risk of amyotrophic lateral sclerosis (ALS), according to a genetic analysis of nearly 2,900 sporadic ALS patients. Such mutations were found to affect the maturation and survival of…
Search results for:
Diminished activity in the C9orf72 gene that is linked with amyotrophic lateral sclerosis (ALS) affected the neuromuscular junction — where nerve and muscle cells connect — in a zebrafish model, establishing the model as a disease research tool and the gene’s role in ALS symptoms. Zebrafish in this C9orf72 loss-of-function model…
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects motor neurons, or nerve cells controlling muscle movement. The symptoms of ALS can occur at any age but usually begin around ages 55 to 75 and progress gradually. Muscles involved in speech…
Men who played professional soccer were nearly four times more likely to develop a neurodegenerative disorder, including a motor neuron disease such as amyotrophic lateral sclerosis (ALS), than men of similar age in the general population, a long-term analysis found. Risk was greatest in players with longer careers and…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ketamine, PharmaTher’s investigational therapy for amyotrophic lateral sclerosis (ALS). Orphan drug status is intended to encourage the development of therapies for rare diseases affecting fewer than 200,000 people in the U.S. It provides…
Actemra (tocilizumab), an approved treatment for rheumatoid arthritis, was found to be safe and well-tolerated, and to reduce a key marker of inflammation in amyotrophic lateral sclerosis (ALS) patients with evidence of systemic inflammation in a Phase 2 study. Trial results did not demonstrate that Actemra could slow ALS disability…
Patient enrollment has begun for Cytokinetics‘ pivotal Phase 3 clinical trial investigating reldesemtiv for the treatment of people with early amyotrophic lateral sclerosis (ALS). The global COURAGE-ALS trial (NCT04944784) will enroll approximately 555 adults who are within two years of their first symptom of muscle weakness.
The Paralysis Resource Center (PRC), a comprehensive support program for people with paralysis, was awarded a five-year, multi-million dollar grant by the Administration for Community Living (ACL), part of the U.S. Department of Health and Human Services. Effective as of July, the cooperative agreement between the two runs through June…
The U.S. Food and Drug Administration (FDA) has granted fast track status to Apic Bio’s experimental therapy APB-102, designed for amyotrophic lateral sclerosis (ALS) patients who carry mutations in the SOD1 gene that lead to misfolded proteins in cells. This designation accelerates the development of investigational therapies that…
Mitsubishi Tanabe Pharma America (MTPA) and Target ALS welcome nominations for the Target ALS Rebecca Luker Courage Award, honoring those who have demonstrated courage and made a positive impact on the amyotrophic lateral sclerosis (ALS) community over the past year. “We have dedicated ourselves to a singular…